Topic: Suboxone (Buprenorphine)
Posts concerning buprenorphine, often prescribed with naloxone under the brand name Suboxone.
Governor DeSantis’ Drug Czar, Doug Simon, comments on Medication-Assisted Treatment
In May 2023, CSDAP staff met with Doug Simon, Governor DeSantis’ Director of the Office of Drug Control (a job often referred to as Drug Czar). He commented on the pros and cons of Medication-Assisted Treatment for those addicted to opioids, alcohol or other drugs and what must be done to reduce the state's problems with drugs and addiction.
MAT: Overdose Prevention or Treatment Leading to Real Recovery?
Medication-assisted treatment is America's primary offering for those who are addicted. But implicit in the word “treatment” is recovery from an illness or other condition—as in "not suffering from that condition any longer." Is medication-assisted treatment really a recovery-oriented therapy? Or is its primary role preventing a person from relapse and overdose? These are questions those involved in addiction recovery should be asking.
Will the White House’s “X waiver” elimination have unintended consequences?
According to an article in Politico, the White House held a ceremony on January 24, 2023 to sign the Mainstreaming Addiction Treatment (MAT) Act. This Act eliminated the special training requirement for doctors and other health practitioners who wanted to prescribe medication-assisted treatment to the opioid-addicted. While making medication-assisted treatment more broadly available could be a positive move, does it take into account the care that the opioid-addicted really need ?
Can the scope of addiction treatment be changed with a single word?
Government agencies like the Substance Abuse and Mental Health Services Administration, the Department of Health and Human Services (HHS) and the National Institute on Drug Abuse (NIDA) are continuously involved in setting the standards for treatment of addiction. They publish guidelines for both drug rehab facilities and those seeking rehab. Therefore, the exact wording of their guidelines is of utmost importance. A subtle shift could result in unintended and undesirable changes in treatment.
Indivior must face states’ monopoly claim over opioid addiction drug Suboxone
(Reuters) - Drugmaker Indivior Inc must face a lawsuit by 42 state attorneys general accusing it of using illegal tactics to shield its opioid addiction treatment Suboxone from generic competition, a federal judge has ruled. States have said that the company's conduct forced consumers to pay inflated prices for the treatment amid an epidemic of opioid addiction. U.S. District Judge Mitchell Goldberg in Philadelphia found Monday that a reasonable jury could find that Indivior's switch from a pill to an oral film form of the drug in 2009 was intended to extend its monopoly just as generic manufacturers were poised to begin selling their own pills, a strategy known as product hopping.
Buprenorphine abuse high in Scandinavian countries
BPN is abused more than cocaine, GHB, or ecstasy in Scandinavian countries, where it has gained great popularity as a street drug. Snorting or injecting the non-naloxone preparation is a common recreational activity in Europe, but it has not yet reached great proportions in the United States. But it's only a matter of time until U.S. addicts catch on. BPN cannot be detected by a urine drug screen, and I can envision it gaining use for affluent oxycodone addicts whose private physicians address addiction in a manner more civilized than the local methadone clinic.
A Review of Buprenorphine Diversion and Misuse Internationally
Abstract
Outpatient opioid addiction treatment with sublingual buprenorphine pharmacotherapy (OBOT) has rapidly expanded in the United States and abroad, and, with this increase in medication availability, there have been increasing concerns about its diversion, misuse and related harms. This narrative review defines the behaviors of diversion and misuse, examines how the pharmacology of buprenorphine alone and in combination with naloxone influence its abuse liability, and describes the epidemiological data on buprenorphine diversion and intravenous misuse, risk factors for its intravenous misuse and the unintended consequences of misuse and diversion.
Study of buprenorphine diversion cautions against its misuse
Buprenorphine is approved in many countries for the treatment of opioid use disorder (OUD), but problems with diversion and abuse exist. There is a need to understand how and why patients use diverted buprenorphine, and whether barriers to access contribute to illicit use.
58% reported a history of diverted buprenorphine use, with 37% never receiving a prescription. Approximately one-half (52%) reported using buprenorphine to get high or alter mood, but few (4%) indicated that it was their drug of choice.